Franchi, M.; Garau, D.; Kirchmayer, U.; Di Martino, M.; Romero, M.; De Carlo, I.; Scondotto, S.; Corrao, G.
Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project. Cancers 2020, 12, 839.
https://doi.org/10.3390/cancers12040839
AMA Style
Franchi M, Garau D, Kirchmayer U, Di Martino M, Romero M, De Carlo I, Scondotto S, Corrao G.
Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project. Cancers. 2020; 12(4):839.
https://doi.org/10.3390/cancers12040839
Chicago/Turabian Style
Franchi, Matteo, Donatella Garau, Ursula Kirchmayer, Mirko Di Martino, Marilena Romero, Ilenia De Carlo, Salvatore Scondotto, and Giovanni Corrao.
2020. "Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project" Cancers 12, no. 4: 839.
https://doi.org/10.3390/cancers12040839
APA Style
Franchi, M., Garau, D., Kirchmayer, U., Di Martino, M., Romero, M., De Carlo, I., Scondotto, S., & Corrao, G.
(2020). Effectiveness and Costs Associated to Adding Cetuximab or Bevacizumab to Chemotherapy as Initial Treatment in Metastatic Colorectal Cancer: Results from the Observational FABIO Project. Cancers, 12(4), 839.
https://doi.org/10.3390/cancers12040839
